3-(Trimethoxysilyl)-1-propanamine

We are 3-(Trimethoxysilyl)-1-propanamine CAS:13822-56-5 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests


Chemical Name:3-(Trimethoxysilyl)-1-propanamine
CAS.NO:13822-56-5
Synonyms:3-Aminopropyltrimethoxysilane; (3-Aminopropyl)trimethoxysilane;
(3-Aminopropyl) trimethoxysilane; 3-(Trimethoxysilyl)propan-1-amine;
3-trimethoxysilylpropan-1-amine;
Molecular Formula:C6H17NO3Si
Molecular Weight:179.29000
 
Physical and Chemical Properties:
Density:1.027;
Boiling point:210^oC;
Flash point:82^oC;
Index of Refraction:1.424;
 
Specification:
Appearance:Colorless transparent liquid
Purity(GC):≥98.0%
 
Packing:210 L/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Superior adhesion promoter in RTV silicones and other hybrid sealants.
Excellent adhesion promoter for dificult substrates such as ABC, PVC ad Poly Shyrene.
Applicationful component in primer systems for hybrid and polyurethane sealants.
 




Related News: Because API companies usually adopt a different synthetic route from the original research company, compared with the drug itself, the impurities contained in the generic drug API have not been verified by the original drug for many years of use and require more careful testing and control.149463-65-0 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.(3aR,4S,7R,7aS)-Hexahydro-4,7-methanoisobenzofuran-1,3-dione CAS:14166-28-0 Trial results demonstrated that Oligomannate statistically improved cognitive function in mild-to-moderate AD patients as early as week 4 and the benefit was sustained at each follow-up assessment visit,” Shanghai Green Valley Pharmaceuticals, which developed the drug along with two academic institutions in China, said in a statement.10399-13-0 Patents covering oral and injectable rigosertib have been issued in the US and are expected to provide coverage until at least 2037.DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.